TY - JOUR T1 - Peroxisome Proliferator-Activated Receptor-α Contributes to the Resolution of Inflammation after Renal Ischemia/Reperfusion Injury JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 635 LP - 643 DO - 10.1124/jpet.108.146191 VL - 328 IS - 2 AU - Nimesh S. A. Patel AU - Rosanna di Paola AU - Emanuela Mazzon AU - Domenico Britti AU - Christoph Thiemermann AU - Salvatore Cuzzocrea Y1 - 2009/02/01 UR - http://jpet.aspetjournals.org/content/328/2/635.abstract N2 - This study was designed to elucidate the role of peroxisome proliferator-activated receptor (PPAR)-α in the development of inflammation after ischemia/reperfusion injury of the kidney. We have evaluated the effects of ischemia/reperfusion on renal dysfunction, injury, and inflammation in wild-type mice or mice in which the gene for PPAR-α has been deleted [PPAR-α(-/-)] and then treated with the PPAR-α agonist fenofibrate. Mice were subjected to bilateral renal ischemia (30 min) and reperfusion (24 h) and received fenofibrate (3 mg/kg i.p.) before reperfusion. Plasma creatinine, urea, and aspartate aminotransferase were all used as indicators of renal dysfunction and injury. Kidneys were used for histological and immunohistochemical analysis and markers of inflammation. Fenofibrate significantly attenuated the degree of renal dysfunction, injury, and inflammation caused by ischemia/reperfusion injury. The degree of renal dysfunction, injury, and inflammation caused by ischemia/reperfusion was also significantly augmented in PPAR-α(-/-) mice compared with their wild-type littermates. It is interesting that fenofibrate did not protect PPAR-α(-/-) mice against ischemia/reperfusion injury. Therefore, we propose that ligands of PPAR-α may be useful in the treatment of renal ischemia/reperfusion injury and that endogenous PPAR-α limits the degree of renal dysfunction, injury, and inflammation associated with ischemia/reperfusion injury. The American Society for Pharmacology and Experimental Therapeutics ER -